KOD
$116.00
Kodiak Sciences
$2.65
2.34%
KOD
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($1.16)
Revenue:  $0.00 Mil
Monday
Nov 8
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when KOD reports earnings?
Beat
Meet
Miss

Where is KOD's stock price going from here?
Up
Flat
Down
Stock chart of KOD
Analysts
Summary of analysts' recommendations for KOD
Score
Grade
Pivots
Resistance
$123.40
$119.82
$117.91

$114.33

Support
$112.42
$108.84
$106.93
Tweet
Growth
Description
Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company. It specializes in novel therapeutics to treat chronic and retinal diseases. The company's product candidates consists of KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and Uveitis, KSI-201 for treatment resistant wet AMD and KSI-401 for dry AMD which are in clinical stage. Kodiak Sciences Inc. is based in CA, United States.